Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 5, 2017, Pages 333-340

  Seferovic, Jelena P ^a   Claggett, Brian ^a   Seidelmann, Sara B ^a   Seely, Ellen W ^b   Packer, Milton ^c   Zile, Michael R ^d   Rouleau, Jean L ^e   Swedberg, Karl ^f   Lefkowitz, Martin ^g   Shi, Victor C ^g   Desai, Akshay S ^a   McMurray, John J V ^h   Solomon, Scott D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; SACUBITRIL PLUS VALSARTAN; TRIACYLGLYCEROL; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE; VALSARTAN;

ADULT; ARTICLE; BODY MASS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC CONTROL; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; ION EXCHANGE CHROMATOGRAPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED;

AGED; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENALAPRIL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; TETRAZOLES; VALSARTAN;

EID: 85015455374     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30087-6     Document Type: Article

References (40)

1. 1 McMurray, JJ, Gerstein, HC, Holman, RR, Pfeffer, MA, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
2. 2 Pocock, SJ, Wang, D, Pfeffer, MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27 (2006), 65–75.
3. 3 Badar, AA, Perez-Moreno, AC, Hawkins, NM, et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme. Eur J Heart Fail 17 (2015), 196–204.
4. 4 Velazquez, EJ, Pfeffer, MA, McMurray, JV, et al., for VALIANT Investigators. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 5 (2003), 537–544.
5. 5 McMurray, JJ, Packer, M, Desai, AS, et al., for PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
6. 6 Kristensen, SL, Preiss, D, Jhund, PS, et al., for PARADIGM-HF Investigators and Committees. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail, 9, 2016, e002560.
7. 7 Skali, H, Shah, A, Gupta, DK, et al. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. Circ Heart Fail 8 (2015), 448–454.
8. 8 Gerstein, HC, Swedberg, K, Carlsson, J, et al., CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 168 (2008), 1699–1704.
9. 9 Jordan, J, Stinkens, R, Jax, T, et al. Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension. Clin Pharmacol Ther 101 (2017), 254–263.
10. 10 Wang, CH, Leung, N, Lapointe, N, et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 107 (2003), 1923–1929.
11. 11 McMurray, JJ, Packer, M, Desai, AS, et al., for PARADIGM-HF. Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15 (2013), 1062–1073.
12. 12 McMurray, JJ, Packer, M, Desai, AS, et al., for PARADIGM HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 16 (2014), 817–825.
13. 13 Chamberlain, JJ, Rhinehart, AS, Shaefer, CF Jr, Neuman, A, Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med 164 (2016), 542–552.
14. 14 Mayer, TK, Freedman, ZR, Protein glycosylation in diabetes mellitus: a review of laboratory measurements and of their clinical utility. Clin Chim Acta 127 (1983), 147–184.
15. 15 Sugiuchi, H, Uji, Y, Okabe, H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated α-Cyclodextrin. Clin Chem 41 (1995), 717–723.
16. 16 Wahlefeld, AW, Bergmeyer, HU, (eds.) Methods of Enzymatic Analysis, 2nd English edn., 1974, Academic Press Inc, New York, NY, 1831.
17. 17 Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis, 6th edn., 1964, Little, Brown and Co, Boston, 114.
18. 18 Turner, AJ, Isaac, RE, Coates, D, The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23 (2001), 261–269.
19. 19 Turner, AJ, Neprilysin. Barret, AJ, Rawlings, ND, Woessner, JF, (eds.) Handbook of Proteolytic Enzymes, 2004, Elsevier, Amsterdam, 419–426.
20. 20 Kobalava, Z, Kotovskaya, Y, Averkov, O, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther 34 (2016), 191–198.
21. 21 Birkenfeld, AL, Boschmann, M, Moro, C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J ClinEndocrinol Metab 90 (2005), 3622–3628.
22. 22 Birkenfeld, AL, Budziarek, P, Boschmann, M, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 57 (2008), 3199–3204.
23. 23 Coué, M, Badin, PM, Vila, IK, et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes 64 (2015), 4033–4045.
24. 24 Engeli, S, Birkenfeld, AL, Badin, PM, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 122 (2012), 4675–4679.
25. 25 Heinisch, BB, Vila, G, Resl, M, et al. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia 55 (2012), 1400–1405.
26. 26 Lazo, M, Young, JH, Brancati, FL, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 62 (2013), 3189–3193.
27. 27 Mori, MA, Sales, VM, Motta, FL, et al. Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity. PLoS One, 7, 2012, e44782.
28. 28 Plamboeck, A, Holst, JJ, Carr, RD, Deacon, CF, Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48 (2005), 1882–1890.
29. 29 Willard, JR, Barrow, BM, Zraika, S, Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia, 2016, 10.1007/s00125-016-4172-4 published online Dec 8.
30. 30 Jing, F, Mogi, M, Horiuchi, M, Role of renin-angiotensin-aldosterone system in adiposetissue dysfunction. Molecular Cell Endocrinol 378 (2013), 23–28.
31. 31 Messerli, FH, Weber, MA, Brunner, HR, Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 156 (1996), 1957–2019.
32. 32 van der Zijl, NJ, Moors, CC, Goossens, GH, Hermans, MM, Blaak, EE, Diamant, M, Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 34 (2011), 845–851.
33. 33 Arbin, V, Claperon, N, Fournié-Zaluski, MC, Roques, BP, Peyroux, J, Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats. J Cardiovasc Pharmacol 41 (2003), 254–264.
34. 34 White, WB, Bakris, GL, Bergenstal, RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 162 (2011), 620–626.
35. 35 Scirica, BM, Bhatt, DL, Braunwald, E, et al., for SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
36. 36 Green, JB, Bethel, MA, Armstrong, PW, et al., for TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
37. 37 Pfeffer, MA, Claggett, B, Diaz, R, et al., for ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
38. 38 Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. for LEADER Steering Committee, LEADER trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
39. 39 Marso, SP, Bain, SC, Consoli, A, et al., for SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
40. 40 Zinman, B, Wanner, C, Lachin, JM, et al., for EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.